142 related articles for article (PubMed ID: 25660530)
1. A quantitative lateral flow assay to detect complement activation in blood.
Schramm EC; Staten NR; Zhang Z; Bruce SS; Kellner C; Atkinson JP; Kyttaris VC; Tsokos GC; Petri M; Sander Connolly E; Olson PK
Anal Biochem; 2015 May; 477():78-85. PubMed ID: 25660530
[TBL] [Abstract][Full Text] [Related]
2. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.
Halkjær L; Troldborg A; Pedersen H; Jensen L; Hansen AG; Hansen TK; Bjerre M; Østergaard JA; Thiel S
Front Immunol; 2020; 11():774. PubMed ID: 32431705
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
4. The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.
Troldborg A; Jensen L; Deleuran B; Stengaard-Pedersen K; Thiel S; Jensenius JC
Front Immunol; 2018; 9():581. PubMed ID: 29632534
[TBL] [Abstract][Full Text] [Related]
5. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.
Negoro N; Okamura M; Takeda T; Koda S; Amatsu K; Inoue T; Curd JG; Kanayama Y
Arthritis Rheum; 1989 Oct; 32(10):1233-42. PubMed ID: 2803326
[TBL] [Abstract][Full Text] [Related]
7. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
[TBL] [Abstract][Full Text] [Related]
8. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
9. Functional assessment of mouse complement pathway activities and quantification of C3b/C3c/iC3b in an experimental model of mouse renal ischaemia/reperfusion injury.
Kotimaa JP; van Werkhoven MB; O'Flynn J; Klar-Mohamad N; van Groningen J; Schilders G; Rutjes H; Daha MR; Seelen MA; van Kooten C
J Immunol Methods; 2015 Apr; 419():25-34. PubMed ID: 25733354
[TBL] [Abstract][Full Text] [Related]
10. A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces.
Gemmell CH
J Biomed Mater Res; 1997 Dec; 37(4):474-80. PubMed ID: 9407295
[TBL] [Abstract][Full Text] [Related]
11. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3.
Luo S; Hartmann A; Dahse HM; Skerka C; Zipfel PF
J Immunol; 2010 Aug; 185(4):2164-73. PubMed ID: 20644161
[TBL] [Abstract][Full Text] [Related]
12. Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers.
Calano SJ; Shih PA; Liu CC; Kao AH; Navratil JS; Manzi S; Ahearn JM
Adv Exp Med Biol; 2006; 586():381-90. PubMed ID: 16893085
[TBL] [Abstract][Full Text] [Related]
13. ELISA for evaluating the incorporation of plasma derived complement split-products C3b/iC3b into solid-phase immune complexes.
Zimmermann-Nielsen E; Svehag SE; Thorlacius-Ussing O; Baatrup G
J Immunol Methods; 2001 Mar; 249(1-2):43-51. PubMed ID: 11226462
[TBL] [Abstract][Full Text] [Related]
14. Activation and deposition of human breast-milk complement C3 opsonins on serum sensitive Escherichia coli 0111.
Ogundele MO
J Reprod Immunol; 2000; 48(2):99-105. PubMed ID: 11011075
[TBL] [Abstract][Full Text] [Related]
15. Impaired C3b/iC3b deposition on Streptococcus pneumoniae in serum from patients with systemic lupus erythematosus.
Goldblatt F; Yuste J; Isenberg DA; Rahman A; Brown J
Rheumatology (Oxford); 2009 Dec; 48(12):1498-501. PubMed ID: 19797312
[TBL] [Abstract][Full Text] [Related]
16. Pattern of C3, iC3b, and C3d in patients hospitalized for acute asthma.
Lin RY; Caveliere LF; Lorenzana FG; Go EF; Altman KA
Ann Allergy; 1992 Apr; 68(4):324-30. PubMed ID: 1558328
[TBL] [Abstract][Full Text] [Related]
17. Complement activation on solid surfaces as determined by C3 deposition and hemolytic consumption.
Liu L; Elwing H
J Biomed Mater Res; 1994 Jul; 28(7):767-73. PubMed ID: 8083244
[TBL] [Abstract][Full Text] [Related]
18. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
Tamerius JD; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
[TBL] [Abstract][Full Text] [Related]
19. Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease.
Ekdahl KN; Norberg D; Bengtsson AA; Sturfelt G; Nilsson UR; Nilsson B
Clin Vaccine Immunol; 2007 May; 14(5):549-55. PubMed ID: 17344343
[TBL] [Abstract][Full Text] [Related]
20. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
